Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
NRIX
Nurix Therapeutics, Inc.
Nurix's pipeline is oncology-focused with BTK/BRAF degraders and IRAK4 degrader in collaboration, aligning with Biotech - Oncology.
|
$1.31B |
$17.19
+1.12%
|
|
AXGN
AxoGen, Inc.
Axogen's Avance Nerve Graft and Axoguard nerve-repair products are surgical devices used in peripheral nerve repair.
|
$1.31B |
$28.57
+0.87%
|
|
NEOG
Neogen Corporation
MDS pathogen detection platform and Petrifilm-based environmental testing are diagnostic equipment offerings.
|
$1.31B |
$6.05
+0.83%
|
|
AHCO
AdaptHealth Corp.
Direct provider of Home Health & Hospice services and in-home patient care.
|
$1.30B |
$9.62
-0.62%
|
|
ARDT
Ardent Health Partners, LLC
Ardent operates hospitals delivering acute inpatient and related hospital services.
|
$1.30B |
$9.05
-0.82%
|
|
ASTH
Astrana Health, Inc.
Astrana operates outpatient clinics and ambulatory surgical centers, i.e., care delivery services.
|
$1.29B |
$23.06
-0.69%
|
|
STAA
STAAR Surgical Company
STAAR directly manufactures ophthalmic medical devices, primarily implantable lenses (EVO ICL) used for vision correction.
|
$1.29B |
$26.04
-0.65%
|
|
ELVN
Enliven Therapeutics, Inc.
Directly develops oncology therapeutics (small-molecule kinase inhibitors) for cancer, including lead assets ELVN-001 (BCR-ABL) and ELVN-002 (HER2).
|
$1.29B |
$21.65
-0.23%
|
|
SDGR
Schrödinger, Inc.
The company operates a proprietary drug discovery pipeline with programs in oncology, aligning with Biotech - Oncology.
|
$1.28B |
$17.44
-0.06%
|
|
BLFS
BioLife Solutions, Inc.
Sells consumables such as hPL, CellSeal vials, and CryoCase used within CGT workflows.
|
$1.28B |
$26.70
-1.07%
|
|
AMPH
Amphastar Pharmaceuticals, Inc.
Amphastar is advancing biosimilar programs (AMP-004) and positions biosimilars as a core growth pillar.
|
$1.27B |
$27.35
-1.23%
|
|
CLOV
Clover Health Investments, Corp.
Clover Health operates Medicare Advantage plans and provides health insurance benefits.
|
$1.26B |
$2.45
+1.24%
|
|
CTS
CTS Corporation
CTS targets medical end-markets with diagnostic/sensor applications; tagged under Medical Devices & Biometrics.
|
$1.26B |
$42.58
+0.15%
|
|
NKTR
Nektar Therapeutics
NKTR's core immunology focus with REZPEG and TNFR2 antibody programs aligns with Immunology Therapeutics.
|
$1.25B |
$65.79
+9.01%
|
|
SSII
SS Innovations International, Inc.
Core product: robotic surgical system and endo-surgical instruments (SSi Mantra and related tools) sold as surgical equipment.
|
$1.24B |
$6.02
-0.66%
|
|
XNCR
Xencor, Inc.
Company develops and advances bispecific antibodies (XmAb 2+1 formats) for oncology and autoimmune indications.
|
$1.24B |
$17.39
+0.75%
|
|
TRML
Tourmaline Bio, Inc.
Pacibekitug is a monoclonal antibody therapeutic targeting IL-6, fitting Monoclonal Antibody Therapeutics.
|
$1.23B |
$47.98
+0.01%
|
|
CVAC
CureVac N.V.
CureVac's core focus is oncology immunotherapies and cancer vaccines built on its mRNA platform (Biotech - Oncology).
|
$1.23B |
$5.49
+3.98%
|
|
WVE
Wave Life Sciences Ltd.
Wave Life Sciences' core products are stereopure oligonucleotides and oligonucleotide therapeutics (antisense/siRNA/editing AIMers) used as RNA medicines.
|
$1.22B |
$7.69
+3.50%
|
|
INBX
Inhibrx Biosciences, Inc.
Clinical-stage oncology biotech with DR5 and OX40 antibody programs.
|
$1.21B |
$83.74
+1.28%
|
|
PHAR
Pharming Group N.V.
Core rare-disease therapeutic developer focused on RUCONEST and an expanding rare-disease pipeline.
|
$1.20B |
$17.46
+2.36%
|
|
TNGX
Tango Therapeutics, Inc.
Directly develops oncology therapies (biotech) targeting genetically defined cancers, aligning with Biotech - Oncology.
|
$1.20B |
$10.76
+1.80%
|
|
KOD
Kodiak Sciences Inc.
Kodiak is developing ophthalmic drugs (intravitreal biologics) for retinal diseases, making Ophthalmic Drugs a core product category.
|
$1.19B |
$22.44
-2.39%
|
|
IRMD
IRadimed Corporation
The MRidium MRI-compatible patient vital signs monitoring system qualifies as patient monitoring equipment in MRI environments.
|
$1.18B |
$92.78
+0.60%
|
|
ANAB
AnaptysBio, Inc.
Company develops immunology therapeutics targeting autoimmune/inflammatory diseases (e.g., rosnilimab, ANB033, ANB101).
|
$1.18B |
$42.15
+1.57%
|
|
TYRA
Tyra Biosciences, Inc.
TYRA-300 is an oral FGFR3-selective small-molecule inhibitor; TYRA develops oral small-molecule therapeutics.
|
$1.17B |
$22.01
+0.50%
|
|
TIC
TIC Solutions, Inc.
Laboratory Testing & Advisory Services aligns with Acuren's lab-based destructive testing capabilities and analytical advisory work.
|
$1.17B |
$9.52
-1.04%
|
|
XERS
Xeris Biopharma Holdings, Inc.
Xeris's XeriSol and XeriJect drug-delivery platforms enable stable, ready-to-use injectable formulations, a core differentiator.
|
$1.16B |
$7.18
+1.20%
|
|
CSTL
Castle Biosciences, Inc.
Castle Biosciences provides oncology biomarker diagnostics (DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher BE) using gene expression profiling and spatial omics, aligning with Biotech - Oncology.
|
$1.16B |
$39.98
+0.13%
|
|
NNE
Nano Nuclear Energy Inc
Company engages in laboratory testing/advisory services related to nuclear tech development and regulatory readiness.
|
$1.16B |
$30.84
+1.92%
|
|
ORIC
ORIC Pharmaceuticals, Inc.
ORIC develops oncology therapies (e.g., ORIC-944, ORIC-114, ORIC-533) targeting cancer resistance, placing it in Biotech - Oncology.
|
$1.15B |
$11.82
+1.72%
|
|
UCTT
Ultra Clean Holdings, Inc.
Provides laboratory testing and advisory services relevant to semiconductor manufacturing cleanliness and optimization.
|
$1.14B |
$25.15
+1.00%
|
Showing page 13 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
